STA
PGNX

Summit Trail Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Summit Trail Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-73,366
Closed -$408K – 715
2018
Q1 		$408K Buy
73,366
+8,495
+13% +$56.5K 0.07% 233
2017
Q4 		$424K Buy
+64,871
New +$394K 0.05% 254

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Summit Trail Advisors's PGNX Position: Q2 2018 in Review

Summit Trail Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2018, closing a stake of 73,366 shares — an estimated $408K sold.

Summit Trail Advisors first reported a position in PGNX in Q4 2017 and held it in 2 quarters. The position peaked at $424K in Q4 2017. 155 funds tracked by Wall St. Rank hold PGNX as of Q2 2018.

  • Summit Trail Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 73,366 Progenics Pharmaceuticals Inc shares in Q2 2018, an estimated $408K.
  • Summit Trail Advisors first reported a position in Progenics Pharmaceuticals Inc in Q4 2017 and held it in 2 quarters.
  • Summit Trail Advisors's Progenics Pharmaceuticals Inc position peaked at $424K in Q4 2017.
  • 155 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2018.

Based on Summit Trail Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.